JP7354306B2 - 新規icos抗体及びそれらを含む腫瘍標的化抗原結合分子 - Google Patents
新規icos抗体及びそれらを含む腫瘍標的化抗原結合分子 Download PDFInfo
- Publication number
- JP7354306B2 JP7354306B2 JP2021576443A JP2021576443A JP7354306B2 JP 7354306 B2 JP7354306 B2 JP 7354306B2 JP 2021576443 A JP2021576443 A JP 2021576443A JP 2021576443 A JP2021576443 A JP 2021576443A JP 7354306 B2 JP7354306 B2 JP 7354306B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000027455 binding Effects 0.000 title claims description 729
- 239000000427 antigen Substances 0.000 title claims description 599
- 108091007433 antigens Proteins 0.000 title claims description 597
- 102000036639 antigens Human genes 0.000 title claims description 597
- 206010028980 Neoplasm Diseases 0.000 title claims description 183
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 739
- 230000001270 agonistic effect Effects 0.000 claims description 205
- 210000004027 cell Anatomy 0.000 claims description 167
- 241000282414 Homo sapiens Species 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 64
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 58
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 58
- 230000009870 specific binding Effects 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 238000006467 substitution reaction Methods 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 102000009109 Fc receptors Human genes 0.000 claims description 46
- 108010087819 Fc receptors Proteins 0.000 claims description 46
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 45
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 239000012636 effector Substances 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 33
- 230000002494 anti-cea effect Effects 0.000 claims description 32
- 230000003993 interaction Effects 0.000 claims description 32
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 22
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 230000003213 activating effect Effects 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 102220562703 Protein Tob2_L234A_mutation Human genes 0.000 claims description 11
- 210000002950 fibroblast Anatomy 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 229960003852 atezolizumab Drugs 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 230000004614 tumor growth Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000002619 cancer immunotherapy Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 108
- 102000004196 processed proteins & peptides Human genes 0.000 description 83
- 229920001184 polypeptide Polymers 0.000 description 81
- 235000001014 amino acid Nutrition 0.000 description 74
- 108091033319 polynucleotide Proteins 0.000 description 50
- 239000002157 polynucleotide Substances 0.000 description 50
- 102000040430 polynucleotide Human genes 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 43
- 231100000673 dose–response relationship Toxicity 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 38
- 230000006870 function Effects 0.000 description 38
- 229940027941 immunoglobulin g Drugs 0.000 description 37
- 230000003053 immunization Effects 0.000 description 32
- 238000002649 immunization Methods 0.000 description 32
- 108060003951 Immunoglobulin Proteins 0.000 description 31
- 102000018358 immunoglobulin Human genes 0.000 description 31
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 27
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 27
- 101001042093 Mus musculus ICOS ligand Proteins 0.000 description 27
- 125000000539 amino acid group Chemical group 0.000 description 27
- 241000283973 Oryctolagus cuniculus Species 0.000 description 24
- 230000004048 modification Effects 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 239000013598 vector Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000890 antigenic effect Effects 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 19
- 102000010451 Folate receptor alpha Human genes 0.000 description 18
- 108050001931 Folate receptor alpha Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 17
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 14
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 14
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 14
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 210000004899 c-terminal region Anatomy 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 13
- 102100034980 ICOS ligand Human genes 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 102000043396 human ICOS Human genes 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000282567 Macaca fascicularis Species 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 241000282412 Homo Species 0.000 description 11
- 241000288906 Primates Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 241000283984 Rodentia Species 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 8
- 108010073807 IgG Receptors Proteins 0.000 description 8
- 102000009490 IgG Receptors Human genes 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000006044 T cell activation Effects 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 229960003301 nivolumab Drugs 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 229960002621 pembrolizumab Drugs 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 229950009791 durvalumab Drugs 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101710093458 ICOS ligand Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000009824 affinity maturation Effects 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 239000000710 homodimer Substances 0.000 description 5
- 102000048776 human CD274 Human genes 0.000 description 5
- 238000011577 humanized mouse model Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- PIFFQYJYNWXNGE-UHFFFAOYSA-N 2,4-diacetylphloroglucinol Chemical compound CC(=O)C1=C(O)C=C(O)C(C(C)=O)=C1O PIFFQYJYNWXNGE-UHFFFAOYSA-N 0.000 description 4
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102000019298 Lipocalin Human genes 0.000 description 4
- 108050006654 Lipocalin Proteins 0.000 description 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 4
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000857304 Mus musculus Glomulin Proteins 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 4
- 102000025171 antigen binding proteins Human genes 0.000 description 4
- 108091000831 antigen binding proteins Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 230000005746 immune checkpoint blockade Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- -1 see Hudson et al. Proteins 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 3
- 102000008102 Ankyrins Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000005734 heterodimerization reaction Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 102000048362 human PDCD1 Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 2
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000002090 Fibronectin type III Human genes 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 2
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 101100179075 Mus musculus Icos gene Proteins 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- IKAIKUBBJHFNBZ-UHFFFAOYSA-N glycyl-lysine Chemical group NCCCCC(C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-UHFFFAOYSA-N 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000002500 microbody Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000007420 radioactive assay Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229940121351 vopratelimab Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZSZXYWFCIKKZBT-IVYVYLGESA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-IVYVYLGESA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 description 1
- ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-piperidin-4-yloxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCNCC1 ZYPDJSJJXZWZJJ-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000775749 Homo sapiens Proto-oncogene vav Proteins 0.000 description 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 102220506058 Intraflagellar transport protein 57 homolog_K409D_mutation Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102220519587 Keratinocyte-associated protein 3_K392D_mutation Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 101000933447 Mus musculus Beta-glucuronidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108091006036 N-glycosylated proteins Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000006964 Nevi and Melanomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710129873 Prolyl endopeptidase FAP Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102220486066 Protein YAE1 homolog_D265A_mutation Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 102000013069 gamma-Crystallins Human genes 0.000 description 1
- 108010079934 gamma-Crystallins Proteins 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 102000046492 human ICOSLG Human genes 0.000 description 1
- 102000049443 human SMCP Human genes 0.000 description 1
- 102000051860 human VAV1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000032226 immune complex clearance Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
- 235000007635 levomefolic acid Nutrition 0.000 description 1
- 239000011578 levomefolic acid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 102200020268 rs1057519181 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Description
一態様では、本発明は、腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインと、ICOSへの特異的結合能を有する少なくとも1つの抗原結合ドメインとを含むアゴニスト性ICOS抗原結合分子であって、
一態様では、上に定義される腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインを含むアゴニスト性ICOS結合分子であって、腫瘍関連抗原への特異的結合能を有する抗原結合ドメインが、癌胎児性抗原(CEA)への特異的結合能を有する抗原結合ドメインである、アゴニスト性ICOS結合分子が提供される。一態様では、CEAへの特異的結合能を有する抗原結合ドメインは、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、アゴニスト性ICOS結合分子が提供される。
(a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する1つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、アゴニスト性ICOS抗原結合分子を提供する。特に、アゴニスト性ICOS抗原結合分子は、アミノ酸変異L234A、L235A及びP329G(Kabat EUインデックスによるナンバリング)を含む、ヒトIgG1サブクラスのFcドメインを含む。
(a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する2つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、アゴニスト性ICOS抗原結合分子を提供する。特に、ヒトIgG1サブクラスのFcドメインは、アミノ酸変異L234A、L235A及びP329G(Kabat EUインデックスによるナンバリング)を含む。
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、アゴニスト性ICOS抗原結合分子、特に抗体が提供される。
(i)T細胞応答の刺激、
(ii)活性化T細胞の生残の支持、
(iii)感染の処置、
(iv)がんの処置、
(v)がんの進行の遅延、又は
(vi)がんを患う患者の生存の延長。
他の意味であると定義されない限り、本明細書で使用される技術用語及び科学用語は、本発明が属する技術分野で一般的に使用されるのと同じ意味を有する。本明細書を解釈する目的で、以下の定義が適用され、適切な場合にはいつでも、単数形で使用される用語は、複数形も含み、その逆に、複数形で使用される用語は、単数形も含む。
一般に、抗体は6つのCDRを含み、3つがVH中にあり(CDR-H1、CDR-H2、CDR-H3)、3つがVL中にある(CDR-L1、CDR-L2、CDR-L3)。本明細書における例示的なCDRとしては、
(a)アミノ酸残基26~32(L1)、50~52(L2)、91~96(L3)、26~32(H1)、53~55(H2)、及び96~101(H3)で生じる超可変ループ(Chothia and Lesk,J.Mol.Biol.196:901-917(1987))、
100×分数X/Y
(1)疎水性:ノルロイシン、Met、Ala、Val、Leu、Ile;
(2)中性親水性:Cys、Ser、Thr、Asn、Gln、
(3)酸性:Asp、Glu;
(4)塩基性:His、Lys、Arg;
(5)鎖配向に影響を及ぼす残基:Gly、Pro;
(6)芳香族:Trp、Tyr、Phe。
非保存的置換は、これらのクラスの1つのメンバーを別のクラスと交換することを伴うであろう。
本発明のアゴニスト性ICOS結合分子
腫瘍関連抗原に結合する少なくとも1つの抗原結合ドメインを含む例示的なアゴニスト性ICOS結合分子
一態様では、本発明は、腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインと、ICOSへの特異的結合能を有する少なくとも1つの抗原結合ドメインとを含むアゴニスト性ICOS抗原結合分子であって、
一態様では、本発明は、そのような二重特異性アゴニスト性ICOS抗原結合分子であって、
(a)ICOSへの特異的結合能を有する少なくとも1つの抗原結合ドメインと、
(b)腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインと、
(c)Fcドメインとを含む、二重特異性アゴニスト性ICOS結合分子を提供する。
一態様では、上に定義される腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインを含むアゴニスト性ICOS結合分子であって、腫瘍関連抗原への特異的結合能を有する抗原結合ドメインが、癌胎児性抗原(CEA)への特異的結合能を有する抗原結合ドメインである、アゴニスト性ICOS結合分子が提供される。一態様では、CEAへの特異的結合能を有する抗原結合ドメインは、
さらに、腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインを含むアゴニスト性ICOS結合分子であって、ICOSへの特異的結合能を有する抗原結合ドメインが、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
一態様では、本発明は、本明細書において前に定義されるアゴニスト性ICOS抗原結合分子であって、
(a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する1つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、アゴニスト性ICOS抗原結合分子を提供する。特に、アゴニスト性ICOS抗原結合分子は、アミノ酸変異L234A、L235A及びP329G(Kabat EUインデックスによるナンバリング)を含む、ヒトIgG1サブクラスのFcドメインを含む。
別の態様では、本発明は、本明細書において前に定義されるアゴニスト性ICOS抗原結合分子であって、
(a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する2つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、アゴニスト性ICOS抗原結合分子を提供する。特に、ヒトIgG1サブクラスのFcドメインは、アミノ酸変異L234A、L235A及びP329G(Kabat EUインデックスによるナンバリング)を含む。
本発明の例示的アゴニスト性ICOS抗体
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、アゴニスト性ICOS抗原結合分子、特に抗体が提供される。
本発明の例示的な二重特異性アゴニスト性ICOS抗原結合分子
Fc受容体結合及び/又はエフェクター機能を低減するFcドメイン改変
ヘテロ二量体化を促進するFcドメイン改変
本発明の例示的なアゴニスト性ICOS抗原結合分子
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
より具体的には、二重特異性抗原結合分子であって、当該分子が、
(i)配列番号42のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号43のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含むか、又は配列番号50のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号51のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含む、FAPへの特異的結合能を有する第1のFab断片と、
(ii)ICOSへの特異的結合能を有する第2のFab断片であって、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHFAP)、及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLFAP)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
更なる態様では、分子は、ICOSへの特異的結合能を有する2つのFab断片を含む。特定の態様では、分子であって、
(i)配列番号42のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号43のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含むか、又は配列番号50のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号51のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含む、FAPへの特異的結合能を有する第1の抗原結合ドメインと、
(ii)ICOSへの特異的結合能を有する2つのFab断片であって、それぞれが、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)、及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、2つのFab断片と、を含む分子が提供される。
特定の態様では、分子であって、
(i)配列番号42のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号43のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含むか、又は配列番号50のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号51のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含む、FAPへの特異的結合能を有する第1のFab断片と、
(ii)ICOSへの特異的結合能を有する2つのFab断片であって、それぞれが、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)、及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%、若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、2つのFab断片と、を含む分子が提供される。
一態様では、配列番号68のアミノ酸配列を含む重鎖可変領域(VHCEA)及び配列番号69のアミノ酸配列を含む軽鎖可変領域(VLCEA)を含むCEAの特異的結合能を有する少なくとも1つの抗原結合ドメインと、ICOSへの特異的結合能を有する少なくとも1つの抗原結合ドメインとを含む、アゴニスト性ICOS結合分子であって、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、アゴニスト性ICOS結合分子が提供される。
(i)配列番号68のアミノ酸配列を含む重鎖可変領域(VHCEA)と配列番号69のアミノ酸配列を含む軽鎖可変領域(VLCEA)とを含む、CEAへの特異的結合能を有する第1のFab断片と、
(ii)ICOSへの特異的結合能を有する第2のFab断片であって、
(a)配列番号10のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号11のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(b)配列番号18のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(c)配列番号26のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号27のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、又は
(d)配列番号34のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号35のアミノ酸配列と少なくとも約95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)を含む、第2のFab断片と、を含む二重特異性抗原結合分子が提供される。
本発明で使用するための例示的な抗CEA/抗CD3二重特異性抗体
別の態様では、抗CEA/抗CD3二重特異性抗体は、
(a)配列番号226のCDR-H1配列、配列番号227のCDR-H2配列、及び配列番号228のCDR-H3配列を含む重鎖可変領域(VHCEA)、及び/又は配列番号229のCDR-L1配列、配列番号230のCDR-L2配列、及び配列番号231のCDR-L3配列を含む軽鎖可変領域(VLCEA)、又は
(b)配列番号234のCDR-H1配列、配列番号235のCDR-H2配列、及び配列番号236のCDR-H3配列を含む重鎖可変領域(VHCEA)、及び/又は配列番号237のCDR-L1配列、配列番号238のCDR-L2配列、及び配列番号239のCDR-L3配列を含む軽鎖可変領域(VLCEA)を含む、第2の抗原結合ドメインを含む。
(a)配列番号226のCDR-H1配列、配列番号227のCDR-H2配列、及び配列番号228のCDR-H3配列を含む重鎖可変領域(VHCEA)、及び/又は配列番号229のCDR-L1配列、配列番号230のCDR-L2配列、及び配列番号231のCDR-L3配列を含む軽鎖可変領域(VLCEA)、又は
(b)配列番号234のCDR-H1配列、配列番号235のCDR-H2配列、及び配列番号236のCDR-H3配列を含む重鎖可変領域(VHCEA)、及び/又は配列番号237のCDR-L1配列、配列番号238のCDR-L2配列、及び配列番号239のCDR-L3配列を含む軽鎖可変領域(VLCEA)を含む、第3の抗原結合ドメインを含む。
本発明で使用するためのPD-L1/PD-1相互作用を遮断する薬剤
ポリヌクレオチド
組換え方法
アッセイ
1.親和性アッセイ
2.結合アッセイ及び他のアッセイ
3.活性アッセイ
医薬組成物、製剤及び投与経路
治療方法及び組成物
他の薬剤及び処置
製造物品
組換えDNA技術
DNA配列決定
遺伝子合成
細胞培養技術
タンパク質精製
SDS-PAGE
分析用サイズ排除クロマトグラフィー
質量分析法
実施例1
ICOS抗体の生成
1.1 免疫化による新規ICOSバインダーの生成のための抗原及びスクリーニングツールの調製、精製及び特性評価
1.1.1 単量体及び二量体ICOS抗原Fc(kih)融合分子の調製、精製及び特性評価
1.1.2 組換えICOSを発現する安定な細胞株の生成及び特性評価
1.1.3 DNA免疫化のためのICOS発現ベクターの生成
1.2 ウサギ及びマウス免疫化によるICOS特異的009、1167、1143及び1138抗体の生成
1.2.1 免疫化キャンペーン
ICOS抗体009の生成
ICOS抗体1183、1143(NZWウサギ)及び1167(tgウサギ)の生成
1.2.2 ウサギからのB細胞クローニング
EL-4 B5培地
プレートのコーティング
PBMCからのマクロファージ/単球の除去
抗原特異的B細胞の濃縮
免疫蛍光染色及びフローサイトメトリー
B細胞培養
1.2.3 VドメインのPCR増幅
1.2.4 ハイブリドーマの生成
1.2.5 ハイブリドーマ細胞からの抗体配列決定
1.3.1 抗ICOSウサギIgG抗体のクローニング及び発現
1.3.2 ハイブリドーマからのモノクローナル抗体の調製
実施例2
抗ICOS抗体の特性評価
2.1 ヒトICOSへの結合
2.1.1 表面プラズモン共鳴(結合活性+親和性)
2.2 リガンド遮断特性
ビオチン化組換えヒトICOSタンパク質を、実施例2.1における組換えヒトICOS Fc(kih)について記載されるように調製した。
2.3 エピトープ特性評価
2.3.1 競合結合(表面プラズモン共鳴)
実施例3
ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性構築物の生成
3.1 ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性一価抗原結合分子の生成(1+1フォーマット)
3.2 ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性一価抗原結合分子(1+1 head-to-tail形式)の生成
3.3 ICOSについては二価であり、FAPについては一価である、ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性抗原結合分子の生成(2+1フォーマット)
3.4 ICOSについては二価であり、FAPについては一価である、ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性抗原結合分子の生成(2+1 クロスfab-IgG P329G LALA)
3.5 ICOSについては二価であり、FAPについては一価である、ICOS及び線維芽細胞活性化タンパク質(FAP)を標的とする二重特異性抗原結合分子の生成(2+1 クロスfab-IgG P329G LALA逆位)
実施例4
マウス及びウサギ抗ICOS抗体のヒト化
4.1 方法
4.2 アクセプターフレームワークの選択及びその適合
009のヒト化
1138のヒト化
1143のヒト化
4.3 ヒト化バリアント
4.4 ヒト化バリアントのクローニング及び発現
実施例5
抗CEA抗体A5B7のヒト化バリアントの生成
5.1 方法
5.2 アクセプターフレームワークの選択及びその適合
5.3 得られるヒト化CEA抗体のVH及びVL領域
5.4 ヒト化A5B7抗体の選択
5.5表面プラズモン共鳴(BIACORE)を使用した、マウスCEA抗体A5B7のヒト化変異体のFab断片の、ヒトCEAに対する親和性の測定
実施例6
ICOS及び癌胎児性抗原関連細胞接着分子(CEA)を標的とする二重特異性抗原結合分子の生成
6.1 ICOS及び癌胎児性抗原関連細胞接着分子(CEA)を標的とする二重特異性一価抗原結合分子の生成(1+1フォーマット)
分子のIn vitro機能的特性評価
7.1 ICOS発現細胞への抗ICOS抗体の結合(フローサイトメトリー分析)
分子35は親抗体と比較して同様の結合挙動を示すが、分子33及び分子34は親抗体(分子32)と比較してより高いEC50値及びより低い全体的な結合を示す。(図3C)
7.2 Jurkat-NFATレポーター細胞の活性化(発光に基づく分析)
7.3 ICOS-リガンドとの競合(フローサイトメトリー分析)
7.4 ICOS過剰発現細胞、FAP過剰発現細胞又はCEA過剰発現細胞への二重特異性腫瘍標的ICOS分子の結合(フローサイトメトリー分析)
表44:ICOS+CHO細胞への種々の腫瘍標的化抗ICOS分子の結合のEC50値
表45:FAP+NIH/3t3-huFAPクローン19細胞に対する異なる腫瘍標的化抗ICOS分子の結合のEC50値
表46:カニクイザルPBMCに対する異なる二重特異性腫瘍標的化抗ICOS分子の結合のEC50値
表47:カニクイザルPBMCに対する異なるフォーマットの二重特異性腫瘍標的化抗ICOS分子の結合のEC50値
表48:マウス脾細胞への種々の腫瘍標的化抗ICOS分子の結合のEC50値
7.5 腫瘍標的ICOS抗原結合分子の存在下でのTCB媒介性T細胞活性化の増加(フローサイトメトリー分析)
実施例8
T細胞二重特異性(TCB)抗体の調製、精製及び特性評価
4.1 ヒト又はヒト化バインダーを用いたTCB抗体の調製
4.2 2+1フォーマットの抗CEA/抗CD3 T細胞二重特異性抗体(マウスCEAでは二価、マウスCD3では一価)の調製
実施例9
CEACAM5-TCBと組み合わせた腫瘍標的ICOS抗原結合分子のIn vivoでの機能的特性評価
9.1 NSGマウスにおける単回注射後の二重特異性FAP-ICOS(1167)二重特異性抗体の薬物動態学的プロファイル
表50:試験した組成物の説明
9.2 ヒト化マウスにおけるMKN45異種移植片におけるCEACAM5-TCBと組み合わせたFAP-ICOS抗体のIn vivo有効性研究
Tv:(W2/2)×L(W:幅、L:長さ)
表51:試験した組成物の説明
参考文献:
Allen F.,Bobanga J.,et al.,CCL3 in the tumor microenvironment augments the antitumor immune response.J Immunol May 1,2016,196(75.11)
Allison J,Sharma P,Quezada,S.A.,Fu T.Combination immunotherapy for the treatment of cancer,WO2011/041613A2 2009
Bacac M,Fauti T,Sam J,et al.A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody(CEA TCB)for the Treatment of Solid Tumours.Clin Cancer Res.2016 Jul 1;22(13):3286-97.
Bacac M,Klein C,Umana P.CEA TCB:A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumours.Oncoimmunology.2016 Jun 24;5(8).
Carthon B C et al.,“Preoperative CTLA-4 blockade:Tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res.2010 16(10);2861-71.
Dammeijer F.,Lau S.P.,van Eijck C.H.J.,van der Burg S.H.,Aerts J.G.J.V.Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumours.Cytokine&Growth Factor Reviews 2017 Aug;36:5-15.
Davidson E.H.,Hood L.,Dimitrov K.,Direct multiplexed measurement of gene expression with color-coded probe pairs.Nature biotechnology 2008;26:317-325.
Fu T et al.,The ICOS/ICOSL pathway is required for optimal antitumour responses mediated by anti-CTLA-4 therapy.Cancer Res.2011,71(16);5445-54.
Geiss G.K.et al.,Direct multiplexed measurement of gene expression with color-coded probe pairs.Nat Biotechnol.2008 Mar;26(3):317-25.
Giacomo A M D et al.,“Long-term survival and immunological parameters in metastatic melanoma patients who respond to ipilimumab 10 mg/kg within an expanded access program”,Cancer Immunol Immunother.2013,62(6);1021-8.
Gu-Trantien C.,Migliori E.,et al.,CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer.JCI Insight.2017 Jun 2;2(11).
Hutloff A.,Dittrich A.M.,Beier K.C.,Eljaschewitsch B.,Kraft R.,Anagnostopoulos I.,Kroczek R.A.ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.Nature.1999 Jan 21;397(6716):263-6.
Im S.J.,Hashimoto M.,et al..Defining CD8+T cells that provide the proliferative burst after PD-1 therapy.Nature.2016 Sep 15;537(7620):417-421.
Liakou C I et al.,CTLA-4 blockade increases IFN-gamma producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.Proc Natl Acad Sci USA 2008,105(39);14987-92.
Manzoor A.M.,Developing Costimulatory Molecules for Immunotherapy of Diseases,Academic Press,2015;eBook ISBN 9780128026755
Paulos C.M.,Carpenito C.,Plesa G.,Suhoski M.M.,Varela-Rohena A.,Golovina T.N.,Carroll R.G.,Riley J.L.,June C.H.The inducible costimulator(ICOS)is critical for the development of human T(H)17 cells.Sci Transl Med.2010 Oct 27;2(55):55ra78.
Sharma P,Allison J 2015.The future of immune checkpoint therapy.Science 2015;348:56-61
Simpson T.R.,Quezada S.A.,Allison J.P.Regulation of CD4 T cell activation and effector function by inducible costimulator(ICOS).Current Opinion in Immunology 2010,22.
Vonderheide R H et al.,Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells,Clin Cancer Res.2010,16(13);3485-94.
Wakamatsu E.,Mathis D.,Benoist C.Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+T cells.Proc Natl Acad Sci U S A.2013 Jan 15;110(3):1023-8.
Warnatz K.,et al.,Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency.Blood 2006 107:3045-3052
Yao S.,Zhu Y.,Zhu G.,Augustine M.,Zheng L.,Goode D.J.,Broadwater M.,Ruff W.,Flies S.,Xu H.,Flies D.,Luo L.,Wang S.,Chen L.B7-h2 is a costimulatory ligand for CD28 in human.Immunity.2011 May 27;34(5):729-40.
Young,M.R.I.,Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.J Clin Cell Immunol.2016 Jun;7(3):431.
Yuraszeck et al.,Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Clinical Pharmacology&Therapeutics 2017,101
Claims (32)
- 腫瘍関連抗原への特異的結合能を有する少なくとも1つの抗原結合ドメインと、ICOSへの特異的結合能を有する少なくとも1つの抗原結合ドメインとを含む、アゴニスト性ICOS抗原結合抗体分子であって、
(i)配列番号12のアミノ酸配列を含むCDR-H1、(ii)配列番号13のアミノ酸配列を含むCDR-H2、及び(iii)配列番号14のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHICOS)、並びに(iv)配列番号15のアミノ酸配列を含むCDR-L1、(v)配列番号16のアミノ酸配列を含むCDR-L2、及び(vi)配列番号17のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLICOS)、を含み、Fc受容体に対する抗原結合抗体分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む、安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインを更に含む、アゴニスト性ICOS抗原結合抗体分子。 - アミノ酸変異L234A、L235A及びP329G(Kabat EUインデックスによるナンバリング)を含むヒトIgG1サブクラスのFcドメインを含む、請求項1に記載のアゴニスト性ICOS抗原結合抗体分子。
- 腫瘍関連抗原への特異的結合能を有する抗原結合ドメインが、癌胎児性抗原(CEA)への特異的結合能を有する抗原結合ドメインである、請求項1又は2に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記CEAへの特異的結合能を有する抗原結合ドメインが、
(a)(i)配列番号52のアミノ酸配列を含むCDR-H1、(ii)配列番号53のアミノ酸配列を含むCDR-H2、及び(iii)配列番号54のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHCEA)、並びに(iv)配列番号55のアミノ酸配列を含むCDR-L1、(v)配列番号56のアミノ酸配列を含むCDR-L2、及び(vi)配列番号57のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLCEA)、又は
(b)(i)配列番号60のアミノ酸配列を含むCDR-H1、(ii)配列番号61のアミノ酸配列を含むCDR-H2、及び(iii)配列番号62のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHCEA)、並びに(iv)配列番号63のアミノ酸配列を含むCDR-L1、(v)配列番号64のアミノ酸配列を含むCDR-L2、及び(vi)配列番号65のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLCEA)、を含む、請求項1~3のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - 前記CEAへの特異的結合能を有する抗原結合ドメインが、配列番号58のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一のアミノ酸配列を含む重鎖可変領域(VHCEA)及び配列番号59のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一のアミノ酸配列を含む軽鎖可変領域(VLCEA)、又は配列番号68のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一のアミノ酸配列を含む重鎖可変領域(VHCEA)及び配列番号69のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一のアミノ酸配列を含む軽鎖可変領域(VLCEA)を含む、請求項1~4のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記CEAへの特異的結合能を有する抗原結合ドメインが、配列番号68のアミノ酸配列を含む重鎖可変領域(VHCEA)及び配列番号69のアミノ酸配列を含む軽鎖可変領域(VLCEA)を含む、請求項1~5のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 腫瘍関連抗原への特異的結合能を有する抗原結合ドメインが、線維芽細胞活性化タンパク質(FAP)への特異的結合能を有する抗原結合ドメインである、請求項1又は2のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記FAPへの特異的結合能を有する抗原結合ドメインが、
(a)(i)配列番号36のアミノ酸配列を含むCDR-H1、(ii)配列番号37のアミノ酸配列を含むCDR-H2、及び(iii)配列番号38のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHFAP)、並びに(iv)配列番号39のアミノ酸配列を含むCDR-L1、(v)配列番号40のアミノ酸配列を含むCDR-L2、及び(vi)配列番号41のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLFAP)、又は
(b)(i)配列番号44のアミノ酸配列を含むCDR-H1、(ii)配列番号45のアミノ酸配列を含むCDR-H2、及び(iii)配列番号46のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHFAP)、並びに(iv)配列番号47のアミノ酸配列を含むCDR-L1、(v)配列番号48のアミノ酸配列を含むCDR-L2、及び(vi)配列番号49のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLFAP)、を含む、請求項1又は2又は7のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - 前記FAPへの特異的結合能を有する抗原結合ドメインが、
(a)配列番号42のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号43のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLFAP)、又は
(b)配列番号50のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号51のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLFAP)、を含む、請求項1又は2又は7又は8のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - FAPへの特異的結合能を有する前記抗原結合ドメインが、配列番号42のアミノ酸配列を含む重鎖可変領域(VHFAP)及び配列番号43のアミノ酸配列を含む軽鎖可変領域(VLFAP)を含む、請求項1又は2又は7~9のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- ICOSへの特異的結合能を有する前記抗原結合ドメインが、
配列番号18のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)及び配列番号19のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、を含む、請求項1~10のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - (a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する1つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、請求項1~11のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - (a)腫瘍関連抗原への特異的結合能を有する1つの抗原結合ドメインと、
(b)ICOSへの特異的結合能を有する2つのFab断片と、
(c)Fc受容体に対する抗原結合分子の結合親和性及び/又はエフェクター機能を低下させる1つ以上のアミノ酸置換を含む安定な会合が可能な第1及び第2のサブユニットで構成されるFcドメインと、を含む、請求項1~11のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。 - 腫瘍関連抗原への特異的結合能を有する前記抗原結合ドメインがクロスFab断片である、請求項12又は13に記載のアゴニスト性ICOS抗原結合抗体分子。
- アゴニスト性ICOS抗原結合抗体分子であって、
(i)配列番号12のアミノ酸配列を含むCDR-H1、(ii)配列番号13のアミノ酸配列を含むCDR-H2、及び(iii)配列番号14のアミノ酸配列を含むCDR-H3を含む重鎖可変領域(VHICOS)、並びに(iv)配列番号15のアミノ酸配列を含むCDR-L1、(v)配列番号16のアミノ酸配列を含むCDR-L2、及び(vi)配列番号17のアミノ酸配列を含むCDR-L3を含む軽鎖可変領域(VLICOS)、を含む、アゴニスト性ICOS抗原結合抗体分子。 - アゴニスト性ICOS抗原結合抗体分子であって、
配列番号18のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む重鎖可変領域(VHICOS)、及び配列番号19のアミノ酸配列と少なくとも95%、96%、97%、98%、99%若しくは100%同一であるアミノ酸配列を含む軽鎖可変領域(VLICOS)、を含む、請求項15に記載のアゴニスト性ICOS抗原結合抗体分子。 - 請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子をコードする単離核酸。
- 請求項17に記載の核酸を含む、宿主細胞。
- アゴニスト性ICOS抗原結合抗体分子を製造する方法であって、前記アゴニスト性ICOS抗原結合抗体分子の発現に適した条件下で、請求項18に記載の宿主細胞を培養することを含む、方法。
- 前記抗原結合抗体分子を前記宿主細胞から回収することを更に含む、請求項19に記載の方法。
- 請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子と、少なくとも1つの薬学的に許容可能な賦形剤とを含む、医薬組成物。
- がんの処置に使用するための、請求項21に記載の医薬組成物。
- 医薬として使用するための、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子又は請求項21に記載の医薬組成物。
- がんの処置に使用するための、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子又は請求項21に記載の医薬組成物。
- 前記アゴニスト性ICOS抗原結合抗体分子が、化学療法剤、放射線療法、及び/又はがん免疫療法で使用するための他の薬剤と組み合わせて投与されるためのものである、がんの処置に使用するための、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記アゴニスト性ICOS抗原結合抗体分子が、T細胞活性化抗CD3二重特異性抗体と組み合わせて投与されるためのものである、がんの処置における使用のための、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記T細胞活性化抗CD3二重特異性抗体が抗CEA/抗CD3二重特異性抗体である、請求項26に記載の使用のための請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- 前記アゴニスト性ICOS抗原結合抗体分子が、PD-L1/PD-1相互作用を遮断する薬剤と組み合わせて使用するためのものである、がんの処置における使用のための請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- PD-L1/PD-1相互作用を遮断する薬剤がアテゾリズマブである、請求項28に記載の使用のための請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子。
- がんの処置のための医薬の製造における、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子又は請求項21に記載の医薬組成物の使用。
- 個体において腫瘍細胞の成長を阻害するための医薬であって、有効量の、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子又は請求項21に記載の医薬組成物を含む、医薬。
- がんを処置するための医薬であって、治療有効量の、請求項1~16のいずれか一項に記載のアゴニスト性ICOS抗原結合抗体分子又は請求項21に記載の医薬組成物を含む、医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19182810.2 | 2019-06-27 | ||
EP19182810 | 2019-06-27 | ||
PCT/EP2020/067572 WO2020260326A1 (en) | 2019-06-27 | 2020-06-24 | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022538102A JP2022538102A (ja) | 2022-08-31 |
JP7354306B2 true JP7354306B2 (ja) | 2023-10-02 |
Family
ID=67105834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021576443A Active JP7354306B2 (ja) | 2019-06-27 | 2020-06-24 | 新規icos抗体及びそれらを含む腫瘍標的化抗原結合分子 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220098305A1 (ja) |
EP (1) | EP3990492A1 (ja) |
JP (1) | JP7354306B2 (ja) |
CN (1) | CN114531878A (ja) |
WO (1) | WO2020260326A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071426A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Pharmaceutical compositions with resistance to soluble cea |
WO2019086500A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
JP2003512019A (ja) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | 変化したエフェクター機能を有するポリペプチド変異体 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ATE307830T1 (de) | 1999-02-05 | 2005-11-15 | Therapeutic Human Polyclonals | Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
CN1468250A (zh) | 2000-08-03 | 2004-01-14 | ��ķһ����˹��̹ | 在转基因动物中产生人源化抗体 |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
US7585668B2 (en) | 2003-07-15 | 2009-09-08 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006047367A2 (en) | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglubolin expression in non-human transgenic animals |
WO2007019223A1 (en) | 2005-08-03 | 2007-02-15 | Therapeutic Human Polyclonals, Inc. | Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin |
CN101506235B (zh) | 2006-09-01 | 2012-07-25 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
UA113712C2 (xx) | 2010-08-13 | 2017-02-27 | Антитіло до fap і способи його застосування | |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
RS60043B1 (sr) | 2012-11-20 | 2020-04-30 | Sanofi Sa | Anti-ceacam5 antitela i njihova primena |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
GB2519786A (en) * | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
CN111057151B (zh) | 2014-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
SG11201701157UA (en) | 2014-08-29 | 2017-03-30 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
EP3209684B1 (en) | 2014-10-24 | 2020-12-23 | F.Hoffmann-La Roche Ag | Vh-vl-interdomain angle based antibody humanization |
UA122676C2 (uk) | 2014-11-20 | 2020-12-28 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язувальна молекула проти folr1 і cd3, що активує t-клітини |
US10323091B2 (en) * | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
JP2019519223A (ja) * | 2016-05-27 | 2019-07-11 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | 免疫調節タンパク質及び腫瘍抗原に結合する二重特異性結合タンパク質 |
EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
-
2020
- 2020-06-24 CN CN202080045846.0A patent/CN114531878A/zh active Pending
- 2020-06-24 WO PCT/EP2020/067572 patent/WO2020260326A1/en active Application Filing
- 2020-06-24 EP EP20734706.3A patent/EP3990492A1/en active Pending
- 2020-06-24 JP JP2021576443A patent/JP7354306B2/ja active Active
-
2021
- 2021-12-15 US US17/644,526 patent/US20220098305A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007071426A1 (en) | 2005-12-21 | 2007-06-28 | Micromet Ag | Pharmaceutical compositions with resistance to soluble cea |
WO2019086500A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
Also Published As
Publication number | Publication date |
---|---|
WO2020260326A1 (en) | 2020-12-30 |
EP3990492A1 (en) | 2022-05-04 |
JP2022538102A (ja) | 2022-08-31 |
CN114531878A (zh) | 2022-05-24 |
US20220098305A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11608376B2 (en) | Tumor-targeted agonistic CD28 antigen binding molecules | |
AU2015345024B2 (en) | Antigen binding molecules comprising a TNF family ligand trimer | |
US20230355754A1 (en) | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules | |
US20200223925A1 (en) | Tumor-targeted superagonistic cd28 antigen binding molecules | |
US20230416366A1 (en) | Anti-cd3/anti-cd28 bispecific antigen binding molecules | |
US20220017637A1 (en) | Agonistic cd28 antigen binding molecules targeting her2 | |
US20220098305A1 (en) | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them | |
RU2808030C2 (ru) | Нацеленные на опухоль агонистические cd28-антигенсвязывающие молекулы | |
WO2022253867A1 (en) | Agonistic cd28 antigen binding molecules targeting epcam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230403 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230710 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230822 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230920 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7354306 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |